RO5545965

RO5545965 is an investigational small molecule drug developed by Roche for the treatment of schizophrenia, specifically targeting negative symptoms in patients treated with antipsychotics. It is a novel imidazo[4,5-b]pyridine derivative and functions as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly expressed in the striatum that regulates intracellular signaling pathways involved in dopaminergic and glutamatergic neurotransmission. By inhibiting PDE10A, RO5545965 modulates cyclic nucleotide signaling within neurons, which may help alleviate negative symptoms associated with schizophrenia. The drug has undergone phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with schizophrenia[1][2][5][7].